Myfembree 1 mg/1
relugolix, estradiol hemihydrate, and norethindrone acetate · TABLET, FILM COATED · Sumitomo Pharma America, Inc
Myfembree is a tablet, film coated containing relugolix, estradiol hemihydrate, and norethindrone acetate at 1 mg/1, taken oral. Manufactured by Sumitomo Pharma America, Inc.
Key Facts
- Brand Name
- Myfembree
- Generic Name
- relugolix, estradiol hemihydrate, and norethindrone acetate
- NDC Code (Product)
72974-415- Manufacturer
- Sumitomo Pharma America, Inc
- Strength
- 1 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA214846
- Drug Class
- Gonadotropin Releasing Hormone Receptor Antagonist [EPC]
- Marketing Start
- 05/26/2021
Recall History
No Recall HistoryFrequently Asked Questions
What is Myfembree used for?
Myfembree contains relugolix, estradiol hemihydrate, and norethindrone acetate. It is a tablet, film coated taken oral. Consult your doctor for specific uses.
Is Myfembree a controlled substance?
Myfembree is not classified as a controlled substance by the DEA.
What is the generic name for Myfembree?
The generic name for Myfembree is relugolix, estradiol hemihydrate, and norethindrone acetate. There are no other listed brand versions of relugolix, estradiol hemihydrate, and norethindrone acetate.
What is the NDC code for Myfembree 1 mg/1?
The NDC (National Drug Code) for Myfembree 1 mg/1 is 72974-415, listed by Sumitomo Pharma America, Inc.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)